Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOXICAPS vs PARSABIV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.
Calcium-sensing receptor (Ca SR) agonist; increases the sensitivity of the Ca SR to extracellular calcium, thereby decreasing parathyroid hormone (PTH) secretion.
Heart failure (NYHA class II-IV) with reduced ejection fraction,Atrial fibrillation (rate control)
Secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis
0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.
Initial dose 5 mg intravenously three times per week, titrated by 2.5 or 5 mg increments every 4 weeks to a maximum of 15 mg three times per week to achieve target parathyroid hormone levels.
Terminal elimination half-life is approximately 5-7 days (120-168 hours) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
Terminal elimination half-life of 3-5 days, supporting once-weekly subcutaneous dosing.
Primarily renal excretion as unchanged drug; minor hepatic metabolism via CYP3A4 and glucuronidation.
Primarily metabolized via amide hydrolysis and oxidation, with involvement of CYP3A4, CYP2D6, and CYP1A2 as minor pathways.
Digitoxin is primarily excreted via the kidneys (approx. 70-80%) as unchanged drug and metabolites; the remainder undergoes biliary/fecal elimination (approx. 20-30%).
Renal: negligible (<2% unchanged); fecal: primary route via biliary elimination of intact drug and metabolites; not dialyzable.
Digitoxin is approximately 90-97% bound to serum proteins, primarily albumin.
Approximately 90-95% bound to albumin.
Volume of distribution is approximately 0.6 L/kg, indicating extensive tissue binding and distribution; the large Vd reflects accumulation in tissues like myocardium and skeletal muscle.
Approximately 0.29-0.46 L/kg, indicating distribution limited to extracellular fluid.
Oral bioavailability is virtually 100% (90-100%) for Lanoxicaps (digitoxin), with consistent absorption from the gastrointestinal tract.
Subcutaneous: approximately 50% (range 40-60%).
For e GFR <50 m L/min, reduce dose by 50% or extend dosing interval: e GFR 35-50 m L/min: 0.125 mg every 24-48 hours; e GFR 10-34 m L/min: 0.125 mg every 48-72 hours; e GFR <10 m L/min: 0.125 mg every 72-96 hours.
Contraindicated in patients with estimated glomerular filtration rate (e GFR) less than 15 m L/min/1.73 m². No dose adjustment required for e GFR ≥ 15 m L/min/1.73 m².
Severe hepatic impairment (Child-Pugh class C) requires dose reduction by 50-75%; monitor digoxin levels. Avoid in fulminant hepatitis.
No specific guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C) due to lack of data.
Neonates: 4-6 mcg/kg/day; Infants: 6-10 mcg/kg/day; Children 1-5 years: 10-15 mcg/kg/day; Children 6-12 years: 8-10 mcg/kg/day; Adolescents: 3-5 mcg/kg/day. All doses given orally.
Safety and efficacy not established in pediatric patients; no approved dosing recommendations.
Start at lower dose (0.0625-0.125 mg daily) due to reduced renal function and lean body mass; monitor serum creatinine and digoxin levels.
No specific dose adjustments recommended; clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy observed.
Toxicity: Narrow therapeutic index; monitor serum levels; avoid in patients with ventricular fibrillation or outflow obstruction.
None.
Monitor for digitalis toxicity (anorexia, nausea, visual disturbances, arrhythmias). Adjust dose in renal impairment, hypokalemia, hypomagnesemia, hypercalcemia, and hypothyroidism.
Hypocalcemia,Seizures potentially due to severe hypocalcemia,QT interval prolongation,Gastrointestinal bleeding,Adynamic bone disease
Ventricular fibrillation,Hypersensitivity to digitalis glycosides,Wolff-Parkinson-White syndrome with atrial fibrillation,Second- or third-degree AV block (without pacemaker),Hypertrophic obstructive cardiomyopathy
Hypocalcemia
High-fiber foods (bran, oats) and certain foods containing pectin can reduce digoxin absorption; take Lanoxicaps on an empty stomach or at least 1 hour before or 2 hours after meals. St. John's Wort may decrease digoxin levels. Avoid licorice root, which can cause hypokalemia and increase toxicity. Consistent dietary potassium intake is important; avoid potassium supplements unless directed.
No specific food interactions. However, patients should adhere to a renal diet as prescribed, which may include restrictions on phosphorus and calcium intake. Avoid calcium-containing supplements or binders without medical advice due to risk of hypercalcemia.
FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal bradycardia, low birth weight; therapeutic levels near toxic for fetus. Use only if maternal benefit outweighs risk.
In animal reproduction studies, intravenous etelcalcetide administered to pregnant rats during organogenesis at doses 2.5 times the maximum recommended human dose (MRHD) based on AUC caused increased incidences of fetal skeletal variations and reduced fetal body weight. In rabbits, no adverse fetal effects were observed at doses up to 0.7 times the MRHD. No adequate and well-controlled studies in pregnant women exist. In the first trimester, exposure poses unknown but potential teratogenic risk. During the second and third trimesters, the drug may cause fetal hypocalcemia due to PTH suppression. Use only if potential benefit justifies potential risk.
Digoxin is excreted into breast milk at low levels (M/P ratio ~0.6–0.9); infant exposure is subtherapeutic. Considered compatible with breastfeeding, but monitor infant for signs of digoxin toxicity (e.g., arrhythmias, nausea).
No data on etelcalcetide presence in human milk, effects on breastfed infants, or milk production. Animal studies show etelcalcetide is present in rat milk. M/P ratio unknown. Because of the potential for serious adverse reactions including hypocalcemia in nursing infants, advise patients not to breastfeed during treatment and for two weeks after the last dose.
Increased volume of distribution and renal clearance in pregnancy may lower digoxin levels; dose adjustment often needed in third trimester. Monitor levels frequently and increase dose if subtherapeutic. Postpartum, reduce dose as clearance normalizes.
No specific dosage adjustments are recommended for pregnancy due to lack of pharmacokinetic data in pregnant women. However, because of the potential for hypocalcemia, more frequent monitoring of serum calcium is advised, and dose adjustments may be needed to maintain calcium levels within target range. The effect of pregnancy on etelcalcetide pharmacokinetics is unknown.
Lanoxicaps (digoxin) has a high bioavailability (90-100%) compared to standard digoxin tablets; adjust dose when switching formulations to avoid toxicity. Monitor renal function and electrolytes (especially potassium, magnesium, calcium) closely; hypokalemia increases digoxin toxicity risk. Digoxin toxicity can present with arrhythmias (e.g., bidirectional ventricular tachycardia, atrial tachycardia with block) and visual disturbances (yellow-green halos). Use digoxin-specific Fab fragments for life-threatening toxicity. Therapeutic drug monitoring: draw levels at least 6-8 hours after dose; target 0.5-0.9 ng/m L for heart failure, 0.8-2.0 ng/m L for atrial fibrillation.
Monitor serum calcium closely; PARSABIV (etelcalcetide) is a calcimimetic that lowers PTH and serum calcium. Initiate only if corrected serum calcium is above the lower limit of normal. Administer intravenously three times per week during hemodialysis. Dose adjustments needed based on serum calcium and PTH levels. Avoid use with other calcimimetics. May cause significant hypocalcemia, especially in patients with adynamic bone disease.
Take exactly as prescribed; do not miss doses or double up. If a dose is missed, skip it unless close to next dose.,Do not switch between Lanoxicaps and standard digoxin tablets without your doctor's approval due to different absorption.,Report symptoms of toxicity: nausea, vomiting, diarrhea, confusion, visual changes (blurred vision, yellow-green halos), or irregular heartbeat.,Keep regular appointments for blood tests to monitor digoxin levels, kidney function, and electrolytes.,Avoid over-the-counter medications, especially antacids, kaolin-pectin, and some laxatives, which can affect absorption.,Maintain consistent dietary intake of potassium-rich foods (bananas, oranges) and avoid extreme changes in diet.
This medication is given intravenously during your dialysis sessions three times a week.,It works by lowering parathyroid hormone (PTH) levels to help manage secondary hyperparathyroidism.,You will need regular blood tests to monitor your calcium and PTH levels.,Report symptoms of low calcium such as muscle cramps, numbness, tingling around the mouth, or seizures.,Do not take any other medications for secondary hyperparathyroidism unless prescribed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOXICAPS vs PARSABIV, answered by our medical review team.
LANOXICAPS is a Cardiac Glycoside that works by Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.. PARSABIV is a Calcimimetic that works by Calcium-sensing receptor (Ca SR) agonist; increases the sensitivity of the Ca SR to extracellular calcium, thereby decreasing parathyroid hormone (PTH) secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOXICAPS and PARSABIV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOXICAPS is: 0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.. The standard adult dose of PARSABIV is: Initial dose 5 mg intravenously three times per week, titrated by 2.5 or 5 mg increments every 4 weeks to a maximum of 15 mg three times per week to achieve target parathyroid hormone levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOXICAPS and PARSABIV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOXICAPS is classified as Category C. FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal . PARSABIV is classified as Category C. In animal reproduction studies, intravenous etelcalcetide administered to pregnant rats during organogenesis at doses 2.5 times the maximum recommended human dose (MRHD) based on A. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.